Protective effects of selegiline against amyloid beta-induced anxiety-like behavior and memory impairment.
Animals
Amyloid beta-Peptides
/ metabolism
Anxiety
/ drug therapy
Rats
Male
Selegiline
/ pharmacology
Memory Disorders
/ drug therapy
Oxidative Stress
/ drug effects
Alzheimer Disease
/ drug therapy
Disease Models, Animal
Avoidance Learning
/ drug effects
Peptide Fragments
Spatial Memory
/ drug effects
Maze Learning
/ drug effects
Rats, Wistar
Recognition, Psychology
/ drug effects
Behavior, Animal
/ drug effects
Neuroprotective Agents
/ pharmacology
Antioxidants
/ pharmacology
alzheimer's disease
anxiety
oxidative stress
passive avoidance memory
selegiline
spatial memory
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
17
05
2024
received:
22
11
2023
accepted:
26
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
ppublish
Résumé
Alzheimer's disease (AD) is a complex and common neurodegenerative disorder. The present study aimed to investigate the potential effects of selegiline (SEL) on various aspects of memory performance, anxiety, and oxidative stress in an AD rat model induced by intracerebroventricular injection of amyloid beta Oral administration of SEL at a dose of 0.5 mg/kg/day was performed for 30 consecutive days. Following the 30 days, several tests, including the open-field, elevated plus-maze, novel object recognition, Morris water maze, and passive avoidance learning were conducted to assess locomotor activity, anxiety-like behavior, recognition memory, spatial memory, and passive avoidance memory, respectively. The results indicate that the induction of AD in rats led to recognition memory, spatial memory, and passive avoidance memory impairments, as well as increased anxiety. Additionally, the AD rats exhibited a decrease in total antioxidant capacity and an increase in total oxidant status levels, suggesting an imbalance in oxidative-antioxidant status. However, the administration of SEL improved memory performance, reduced anxiety, and modulated oxidative-antioxidant status in AD rats. These findings provide evidence that SEL may alleviate anxiety-like behavior and cognitive deficits induced by Aβ through modulation of oxidative-antioxidant status.
Sections du résumé
BACKGROUND
BACKGROUND
Alzheimer's disease (AD) is a complex and common neurodegenerative disorder. The present study aimed to investigate the potential effects of selegiline (SEL) on various aspects of memory performance, anxiety, and oxidative stress in an AD rat model induced by intracerebroventricular injection of amyloid beta
METHODS
METHODS
Oral administration of SEL at a dose of 0.5 mg/kg/day was performed for 30 consecutive days. Following the 30 days, several tests, including the open-field, elevated plus-maze, novel object recognition, Morris water maze, and passive avoidance learning were conducted to assess locomotor activity, anxiety-like behavior, recognition memory, spatial memory, and passive avoidance memory, respectively.
RESULTS
RESULTS
The results indicate that the induction of AD in rats led to recognition memory, spatial memory, and passive avoidance memory impairments, as well as increased anxiety. Additionally, the AD rats exhibited a decrease in total antioxidant capacity and an increase in total oxidant status levels, suggesting an imbalance in oxidative-antioxidant status. However, the administration of SEL improved memory performance, reduced anxiety, and modulated oxidative-antioxidant status in AD rats.
CONCLUSIONS
CONCLUSIONS
These findings provide evidence that SEL may alleviate anxiety-like behavior and cognitive deficits induced by Aβ through modulation of oxidative-antioxidant status.
Substances chimiques
Amyloid beta-Peptides
0
Selegiline
2K1V7GP655
Peptide Fragments
0
amyloid beta-protein (1-42)
0
Neuroprotective Agents
0
Antioxidants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3599Informations de copyright
© 2024 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.
Références
Ahmadi, N., Mirazi, N., Komaki, A., Safari, S., & Hosseini, A. (2021). Vanillic acid attenuates amyloid β1‐40‐induced long‐term potentiation deficit in male rats: An in vivo investigation. Neurological Research, 43, 562–569.
Ahmadi, N., Safari, S., Mirazi, N., Karimi, S. A., & Komaki, A. (2021). Effects of vanillic acid on Aβ1‐40‐induced oxidative stress and learning and memory deficit in male rats. Brain Research Bulletin, 170, 264–273.
Ahmed, A. B., & Chetia, P. (2023). MAO–B inhibitor “selegiline” attenuates oxidative stress and arthritic parameters in an invitro repurposed studies. Journal of Biomedical Engineering, 40(2), 171–181.
Arabi, A., Karimi, S. A., Salehi, I., Haddadi, R., & Komaki, A. (2023). Effects of sesamin on Aβ1‐‐42‐induced oxidative stress and LTP impairment in a rat model of Alzheimer's disease. Metabolic Brain Disease, 38(5), 1503–1511. https://doi.org/10.1007/s11011‐023‐01191‐w
Arib, O., Rat, P., Molimard, R., Chait, A., Faure, P., & de Beaurepaire, R. (2010). Electrophysiological characterization of harmane‐induced activation of mesolimbic dopamine neurons. European Journal of Pharmacology, 629(1–3), 47–52.
Thies, W., Bleiler, L., & Alzheimer's Association. (2013). 2013 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 9(2), 208–245.
Bai, R., Guo, J., Ye, X.‐Y., Xie, Y., & Xie, T. (2022). Oxidative stress: The core pathogenesis and mechanism of Alzheimer's disease. Ageing Research Reviews, 77, 101619.
Basir, H. S., Mirazi, N., Komaki, A., & Hosseini, A. (2024). Cacao consumption improves passive avoidance memory impairment in a rat model of Alzheimer's disease: The role of hippocampal synaptic plasticity and oxidative stress. Frontiers in Pharmacology, 15, Article 1379264.
Behl, T., Kaur, D., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Andronie‐Cioara, F. L., Toma, M. M., Bungau, S., & Bumbu, A. G. (2021). Role of monoamine oxidase activity in Alzheimer's disease: An insight into the therapeutic potential of inhibitors. Molecules, 26(12), 3724.
Bickford, P. C., Adams, C. E., Boyson, S. J., Curella, P., Gerhardt, G. A., Heron, C., Ivy, G. O., Lin, A. M., Murphy, M. P., Poth, K., Wallace, D. R., Young, D. A., Zahniser, N. R., & Rose, G. M. (1997). Long‐term treatment of male F344 rats with deprenyl: Assessment of effects on longevity, behavior, and brain function. Neurobiology of Aging, 18(3), 309–318.
Briyal, S., Ranjan, A. K., & Gulati, A. (2023). Oxidative stress: A target to treat Alzheimer's disease and stroke. Neurochemistry International, 165, 105509.
Bulgart, H. R., Neczypor, E. W., Wold, L. E., & Mackos, A. R. (2020). Microbial involvement in Alzheimer disease development and progression. Molecular Neurodegeneration, 15, 42.
Cai, M., & Yang, E. J. (2020). Effect of combined electroacupuncture and selegiline treatment in Alzheimer's disease: An animal model. Frontiers in Pharmacology, 11, Article 606480.
Carrillo, M., Kanai, S., Sato, Y., Nokubo, M., Ivy, G., & Kitani, K. (1993). The optimal dosage of (−) deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sciences, 52(24), 1925–1934.
Carrillo, M., Kitani, K., Kanai, S., Sato, Y., Ivy, G., & Miyasaka, K. (1996). Long term treatment with (−) deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain. Life Sciences, 59(13), 1047–1057.
Ghaderi, S., Gholipour, P., Komaki, A., Salehi, I., Rashidi, K., Khoshnam, S. E., & Rashno, M. (2022). p‐Coumaric acid ameliorates cognitive and non‐cognitive disturbances in a rat model of Alzheimer's disease: The role of oxidative stress and inflammation. International Immunopharmacology, 112, 109295.
Ghaderi, S., Rashno, M., Sarkaki, A., & Khoshnam, S. E. (2024). Sesamin mitigates lead‐induced behavioral deficits in male rats: The role of oxidative stress. Brain Research Bulletin, 206, 110852. https://doi.org/10.1016/j.brainresbull.2023.110852
Ghai, R., Nagarajan, K., Arora, M., Grover, P., Ali, N., & Kapoor, G. (2020). Current strategies and novel drug approaches for Alzheimer disease. CNS & Neurological Disorders‐Drug Targets, 19(9), 676–690.
Gholami, M., Kaviani, N., Motaghinejad, M., & Ulloa, L. (2023). Neuroprotective effects of selegiline agent methamphetamine‐prompted mood‐related behavior disorder mediated via 5‐HT2 and D2 receptors. International Journal of Preventive Medicine, 14(1), 78.
Gholipour, P., Komaki, A., Parsa, H., & Ramezani, M. (2022). Therapeutic effects of high‐intensity interval training exercise alone and its combination with ecdysterone against amyloid beta‐induced rat model of Alzheimer's disease: A behavioral, biochemical, and histological study. Neurochemical Research, 47, 2090–2108.
Goverdhan, P., Sravanthi, A., & Mamatha, T. (2012). Neuroprotective effects of meloxicam and selegiline in scopolamine‐induced cognitive impairment and oxidative stress. International Journal of Alzheimer's Disease, 2012, 974013.
Huang, L.‐K., Chao, S.‐P., & Hu, C.‐J. (2020). Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 27(1), 18.
Iraji, A., Khoshneviszadeh, M., Firuzi, O., Khoshneviszadeh, M., & Edraki, N. (2020). Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi‐target directed ligands. Bioorganic Chemistry, 97, 103649.
Ishikawa, T., Okano, M., Minami, A., Tsunekawa, H., Satoyoshi, H., Tsukamoto, Y., Takahata, K., & Muraoka, S. (2019). Selegiline ameliorates depression‐like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity. Behavioural Brain Research, 359, 353–361.
Karimi, S. A., Salehi, I., Shykhi, T., Zare, S., & Komaki, A. (2019). Effects of exposure to extremely low‐frequency electromagnetic fields on spatial and passive avoidance learning and memory, anxiety‐like behavior and oxidative stress in male rats. Behavioural Brain Research, 359, 630–638.
Komaki, A., Hoseini, F., Shahidi, S., & Baharlouei, N. (2016). Study of the effect of extract of Thymus vulgaris on anxiety in male rats. Journal of Traditional and Complementary Medicine, 6(3), 257–261.
Komaki, H., Faraji, N., Komaki, A., Shahidi, S., Etaee, F., Raoufi, S., & Mirzaei, F. (2019). Investigation of protective effects of coenzyme Q10 on impaired synaptic plasticity in a male rat model of Alzheimer's disease. Brain Research Bulletin, 147, 14–21.
Lorenzo, A., & Yankner, B. A. (1994). Beta‐amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proceedings of the National Academy of Sciences, 91(25), 12243–12247.
Mancuso, C., Scapagini, G., Currò, D., Giuffrida Stella, A. M., De Marco, C., Butterfield, D. A., & Calabrese, V. (2007). Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Frontiers in Bioscience, 12, 1107–1123. https://doi.org/10.2741/2130
Marcourakis, T., Camarini, R., Kawamoto, E. M., Scorsi, L. R., & Scavone, C. (2008). Peripheral biomarkers of oxidative stress in aging and Alzheimer's disease. Dementia & Neuropsychologia, 2, 2–8.
Meghana, G., Gowda, D., Chidambaram, S. B., & Osmani, R. A. (2023). Amyloid–β pathology in Alzheimer's Disease: A nano delivery approach. Vibrational Spectroscopy, 126, 103510.
Moore, J. J., & Saadabadi, A. (2022). Selegiline. StatPearls [Internet]. StatPearls Publishing.
Muralikrishnan, D., Samantaray, S., & Mohanakumar, K. P. (2003). D‐deprenyl protects nigrostriatal neurons against 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐induced dopaminergic neurotoxicity. Synapse, 50(1), 7–13.
Nagatsu, T., & Sawada, M. (2006). Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: Possible implications of glial cells. Journal of Neural Transmission. Supplementum, (71), 53–65.
Nazifi, M., Oryan, S., Esfahani, D. E., & Ashrafpoor, M. (2021). The functional effects of piperine and piperine plus donepezil on hippocampal synaptic plasticity impairment in rat model of Alzheimer's disease. Life Sciences, 265, 118802.
Paxinos, G., & Watson, C. (2006). The rat brain in stereotaxic coordinates: Hard cover edition. Elsevier.
Pazini, A. M., Gomes, G. M., Villarinho, J. G., da Cunha, C., Pinheiro, F., Ferreira, A. P. O., Mello, C. F., Ferreira, J., & Rubin, M. A. (2013). Selegiline reverses Aβ 25–35‐induced cognitive deficit in male mice. Neurochemical Research, 38, 2287–2294.
Pérez‐Areales, F. J., Garrido, M., Aso, E., Bartolini, M., de Simone, A., Espargaró, A., Ginex, T., Sabaté, R., Pérez, B., Andrisano, V., Puigoriol‐Illamola, D., Pallàs, M., Luque, F. J., Loza, M. I., Brea, J., Ferrer, I., Ciruela, F., Messeguer, A., & Muñoz‐Torrero, D. (2020). Centrally active multitarget anti‐Alzheimer agents derived from the antioxidant lead CR‐6. Journal of Medicinal Chemistry, 63(17), 9360–9390.
Rahman, K. (2007). Studies on free radicals, antioxidants, and co‐factors. Clinical Interventions in Aging, 2(2), 219–236.
Ramezani, M., Komaki, A., Hashemi‐Firouzi, N., Mortezaee, K., Faraji, N., & Golipoor, Z. (2020). Therapeutic effects of melatonin‐treated bone marrow mesenchymal stem cells (BMSC) in a rat model of Alzheimer's disease. Journal of Chemical Neuroanatomy, 108, 101804.
Rashno, M., Sarkaki, A., Ghaderi, S., & Khoshnam, S. E. (2022). Sesamin: Insights into its protective effects against lead‐induced learning and memory deficits in rats. Journal of Trace Elements in Medicine and Biology, 72, 126993.
Salim, S., Sarraj, N., Taneja, M., Saha, K., Tejada‐Simon, M. V., & Chugh, G. (2010). Moderate treadmill exercise prevents oxidative stress‐induced anxiety‐like behavior in rats. Behavioural Brain Research, 208(2), 545–552.
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021). Alzheimer's disease. The Lancet, 397(10284), 1577–1590.
Tian, Z., Wang, X., Han, T., & Sun, C. (2023). Selegiline ameliorated dyslipidemia and hepatic steatosis in high‐fat diet mice. International Immunopharmacology, 117, 109901.
Tsunekawa, H., Noda, Y., Mouri, A., Yoneda, F., & Nabeshima, T. (2008). Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25–35). Behavioural Brain Research, 190(2), 224–232.
Zare, N., Khalifeh, S., Khodagholi, F., Shahamati, S. Z., Motamedi, F., & Maghsoudi, N. (2015). Geldanamycin reduces Aβ‐associated anxiety and depression, concurrent with autophagy provocation. Journal of Molecular Neuroscience, 57, 317–324.
Zarrinkalam, E., Heidarianpour, A., Salehi, I., Ranjbar, K., & Komaki, A. (2016). Effects of endurance, resistance, and concurrent exercise on learning and memory after morphine withdrawal in rats. Life Sciences, 157, 19–24.
Zhang, F., Lu, J., Zhang, J.‐G., & Xie, J.‐X (2015). Protective effects of a polysaccharide from Spirulina platensis on dopaminergic neurons in an MPTP‐induced Parkinson's disease model in C57BL/6J mice. Neural Regeneration Research, 10(2), 308–313.
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023). Amyloid β‐based therapy for Alzheimer's disease: Challenges, successes and future. Signal Transduction and Targeted Therapy, 8(1), 248.